Digestive Diseases and Sciences

, Volume 55, Issue 6, pp 1752–1760 | Cite as

Association Between Nonalcoholic Fatty Liver Disease and Coronary Artery Calcification

  • Chien-Hua Chen
  • Chiu-Kue Nien
  • Chi-Chieh Yang
  • Yung-Hsiang Yeh
Original Article
First Online:
Received:
Accepted:

Abstract

Background

Both nonalcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD) are closely related to many metabolic disorders. Multislice computed tomography (MSCT) is a reliable noninvasive method in demonstrating coronary plaque. However, the association between coronary artery calcium (CAC) score and NAFLD remains controversial.

Aims

The aim of this study is to evaluate the association between CAC score and NAFLD.

Methods

This retrospective study enrolled 295 consecutive asymptomatic subjects who had both coronary angiography by MSCT and hepatobiliary imaging during self-paid physical check-ups.

Results

NAFLD was found in 41% of the enrolled 295 subjects; gall bladder stones were found in 10.8%, and CAC > 100 with moderate-high risk of CAD was found in 12.9% of subjects. Male gender (odds ratios (OR), 3.087; 95% confidence intervals (CI), 1.092–8.729), increased age (OR, 1.108; 95% CI, 1.067–1.151), diabetes mellitus (DM) (OR, 2.968; 95% CI, 1.129–7.803), and NAFLD (OR, 2.462; 95% CI, 1.065–5.691) were the independent factors that increased the risk of CAC > 100 in binary logistic regression. The prevalence of NAFLD also increased with the severity of CAC score (≤100, 38.1%; 101–400, 58.3%; >400, 64.3%; P = 0.03).

Conclusions

Besides the traditional risk factors, such as male gender, increased age, and DM, NAFLD was also associated with moderate to high risk of CAD (CAC > 100).

Keywords

Nonalcoholic fatty liver disease Multislice computed tomography Coronary artery calcium score 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474.CrossRefPubMedGoogle Scholar
  2. 2.
    Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: An overview. J Gastroenterol Hepatol. 2002;17:1136–1143.CrossRefPubMedGoogle Scholar
  3. 3.
    Chitturi S, Farrell GC, George J. Non-alcoholic fatty liver disease in the Asia-Pacific region: Future shock? J Gastroenterol Hepatol. 2004;19:368–374.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen CH, Huang MH, Yang JC, et al. Prevalence of and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 2006;40:745–752.CrossRefPubMedGoogle Scholar
  5. 5.
    Kojima SI, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954–961.CrossRefPubMedGoogle Scholar
  6. 6.
    Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol. 1991;43:26–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Mathiesen UL, Franzen LE, Aselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis. 2002;34:516–522.CrossRefPubMedGoogle Scholar
  8. 8.
    Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.CrossRefPubMedGoogle Scholar
  9. 9.
    Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann intern Med. 2005;143:722–728.PubMedGoogle Scholar
  10. 10.
    Marchesini G, Bugianesi E, Forlani G, et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923.CrossRefPubMedGoogle Scholar
  11. 11.
    Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579–1584.PubMedGoogle Scholar
  12. 12.
    Mirbagheri SA, Rashidi A, Abdi S, Saedi D, Abouzari M. Liver: an alarm for the heart? Liver International. 2007;27:891–894.CrossRefPubMedGoogle Scholar
  13. 13.
    Arslan U, Turkoglu S, Balcioglu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis. 2007;18:433–436.CrossRefPubMedGoogle Scholar
  14. 14.
    Jinzaki M, Sato K, Tanami Y, et al. Novel method of displaying coronary CT angiography: angiographic view. Circ J. 2006;70:1661–1662.CrossRefPubMedGoogle Scholar
  15. 15.
    Girshman J, Wolff SD. Techniques for quantifying coronary artery calcification. Radiol Clin N Am. 2004;42:767–771.CrossRefGoogle Scholar
  16. 16.
    Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association writing group. Circulation. 1996;94:1175–1192.PubMedGoogle Scholar
  17. 17.
    Agatston AS, Janowitz WR, Kaplan G, Gasso J, Hildner F, Viamonte M. Ultrafast computed tomography detected coronary calcium reflects the angiographic extent of coronary artery atherosclerosis. Am J Cardiol. 1994;74:1272–1274.CrossRefPubMedGoogle Scholar
  18. 18.
    Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. BMJ. 1986;292:13–15.CrossRefPubMedGoogle Scholar
  19. 19.
    Leopold GR, Amberg J, Gosink BB, Mittelstaedt C. Gray scale ultrasonic cholecystography: a comparison with conventional radiological techniques. Radiology. 1976;121:445–448.PubMedGoogle Scholar
  20. 20.
    Barakos JA, Ralls PW, Lapin SA, et al. Cholelithiasis: Evaluation with CT. Radiology. 1987;162:415–418.PubMedGoogle Scholar
  21. 21.
    Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–832.CrossRefPubMedGoogle Scholar
  22. 22.
    Berman DS, Wong ND, Gransar H, et al. Relationship between stress-induced myocardial ischemia and atherosclerosis measured by coronary calcium tomography. J Am Coll. 2004;44:923–930.CrossRefGoogle Scholar
  23. 23.
    He ZX, Hedrick TD, Pratt CM, et al. Severity of coronary artery calcification by electron beam computed tomography predicts silent ischemia. Circulation. 2000;101:244–251.PubMedGoogle Scholar
  24. 24.
    Raggi P, Callister TQ, Cooil B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron beam computed tomography. Circulation. 2000;101:850–855.PubMedGoogle Scholar
  25. 25.
    Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol. 2005;11:4838–4842.PubMedGoogle Scholar
  26. 26.
    Mitchell BD, Hazuda HP, Haffner SM, Patterson JK, Stern MP. High prevalence of angina pectoris in Mexican-American men. A population with reduced risk of myocardial infarction. Ann Epidemiol. 1991;1:415–426.PubMedCrossRefGoogle Scholar
  27. 27.
    Burgstahler C, Reimann A, Beck T, et al. Influence of a lipid-lowering therapy on calcified and noncalcified coronary plaques monitored by multislice detector computed tomography: Results of the new age II pilot study. Investigative Radiology. 2007;42:189–195.CrossRefPubMedGoogle Scholar
  28. 28.
    Hausleiter J, Meyer T, Hadamitzky M, Kastrati A, Martinoff S, Schomig A. Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. J Am Coll Cardiol. 2006;48:312–318.CrossRefPubMedGoogle Scholar
  29. 29.
    Adibi P, Sadeghi M, Mahsa M, Rozati G, Mohseni M. Prediction of coronary atherosclerotic disease with liver transaminase level. Liver International. 2007;27:895–900.CrossRefPubMedGoogle Scholar
  30. 30.
    Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Throm Vasc Biol. 2005;25:193–197.Google Scholar
  31. 31.
    Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: The Insulin Resistance Atherosclerosis Study. Diabetes. 2005;54:3140–3147.CrossRefPubMedGoogle Scholar
  32. 32.
    Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002;35:898–904.CrossRefPubMedGoogle Scholar
  33. 33.
    Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and r-glutamyltransferase and mortality in the United States population. 2009; 136: 477–485.Google Scholar
  34. 34.
    Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894–900.CrossRefPubMedGoogle Scholar
  35. 35.
    Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118:816–826.CrossRefPubMedGoogle Scholar
  36. 36.
    Akabame S, Hamaguchi M, Tomiyasu KI, et al. Evaluation of vulnerable coronary plaques and nonalcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J. 2008;72:618–625.CrossRefPubMedGoogle Scholar
  37. 37.
    Mendez-Sanchez N, Bahena-Aponte J, Chavez-Tapia N, et al. Strong association between gallstones and cardiovascular disease. Am J Gastroenterol. 2005;100:827–830.CrossRefPubMedGoogle Scholar
  38. 38.
    Friedman GD. The relationship between coronary heart disease and gallbladder disease: a critical review. Ann Intern Med. 1968;68:222–235.Google Scholar
  39. 39.
    Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of gallstone disease in an adult population of Taiwan: a epidemiological survey. J Gastroenterol Hepatol. 2006;21:1737–1743.CrossRefPubMedGoogle Scholar
  40. 40.
    Diehl AK, Haffner SM, Hazuda HP, Stern MP. Coronary risk factors and clinical gallbladder disease: an approach to the prevention of gallstones? Am J Public health. 1987;77:841–845.CrossRefPubMedGoogle Scholar
  41. 41.
    Newman AB, Naydeck BL, Sutton-Tyrrell K, Feldman A, Edmundowicz D, Kuller LH. Coronary artery calcification in older adults to age 99: prevalence and risk factors. Circulation. 2001;104:2679–2684.CrossRefPubMedGoogle Scholar
  42. 42.
    McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary artery calcium by race, gender, and age. Results from the multi-ethnic study of atherosclerosis. Circulation. 2006;113:30–37.CrossRefPubMedGoogle Scholar
  43. 43.
    Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673–2678.CrossRefPubMedGoogle Scholar
  44. 44.
    Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med. 2005;22:1354–1358.CrossRefPubMedGoogle Scholar
  45. 45.
    Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in non-alcoholic fatty liver disease. Hepatology. 2005;42:473–478.CrossRefPubMedGoogle Scholar
  46. 46.
    Targher G. Association between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease. Hepatology. 2005;42:974–975.CrossRefPubMedGoogle Scholar
  47. 47.
    McKimmie RL, Daniel KR, Carr JJ, et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study. Am J Gastroenterol. 2008;103:3029–3035.CrossRefPubMedGoogle Scholar
  48. 48.
    Lautamaki R, Borra R, Iozzo P, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2006;291:E282–E290.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Chien-Hua Chen
    • 1
    • 2
    • 3
  • Chiu-Kue Nien
    • 4
  • Chi-Chieh Yang
    • 1
  • Yung-Hsiang Yeh
    • 1
    • 2
  1. 1.Digestive Disease CenterChanghua Show-Chwan Memorial HospitalChanghuaTaiwan
  2. 2.Digestive Disease CenterChang-Bing Show-Chwan Memorial HospitalChanghuaTaiwan
  3. 3.Meiho Institute of TechnologyPingtungTaiwan
  4. 4.Department of Medical ResearchShow-Chwan Memorial HospitalChanghuaTaiwan

Personalised recommendations